Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: Cross-sectional study;Teste calprotectina fecal semiquantitativa na sindrome do intestino irritavel pos-infecciosa e nao pos-infecciosa: Estudo transversal

Sao Paulo Medical Journal

Volumn 133, Issue 4, 2015, Pages 343-349

  David, Liliana Elisabeta ^a   Surdea Blaga, Teodora ^a   Dumitrascu, Dan Lucian ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Gastroenteritis; Inflammation; Inflammatory bowel diseases; Irritable bowel syndrome; Leukocyte L1 antigen complex

Indexed keywords

ADULT; ARTICLE; CALPROTECTIN ELISA KIT; CROHN DISEASE; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; HUMAN TISSUE; INFLAMMATION; IRRITABLE COLON; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ULCERATIVE COLITIS; CHEMISTRY; COMPLICATION; DIFFERENTIAL DIAGNOSIS; ECONOMICS; FECES; GASTROENTERITIS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PILOT STUDY; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKER; CALGRANULIN;

ADULT; BIOMARKERS; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; FECES; FEMALE; GASTROENTERITIS; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84945954550     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-3180.2014.8000815     Document Type: Article

References (32)

1. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91
2. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15-22
3. Shastri Y, Povse N, Stein J. A prospective comparative study for new rapid bedside fecal calprotectin test with an established ELISA to assess intestinal inflammation. Clin Lab. 2009;55(1-2):53-5
4. Saverymuttu SH. Clinical remission in Crohn’s disease-assessment using faecal 111In granulocyte excretion. Digestion. 1986;33(2):74-9
5. Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45(7-8):872-7
6. Sipponen T, Savilahti E, Karkkainen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s disease. Inflamm Bowel Dis. 2008;14(10):1392-8
7. Sipponen T, Bjorkesten CG, Farkkila M, et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment. Scand J Gastroenterol. 2010;45(3):325-31
8. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123(2):450-60
9. Sydora MJ, Sydora BC, Fedorak RN. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohns Colitis. 2012;6(2):207-14
10. Burri E, Beglinger C. Faecal calprotectin - a useful tool in the management of inflammatory bowel disease. Swiss Med Wkly. 2012;142:w13557
11. Parry S, Forgacs I. Intestinal infection and irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2005;17(1):5-9
12. Zanini B, Ricci C, Bandera F, et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol. 2012;107(6):891-9
13. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993;104(6):1832-47
14. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology. 1995;108(5):1566-81
15. Fagerberg UL, Loof L, Merzoug RD, Hansson LO, Finkel Y. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr. 2003;37(4):468-72
16. Roseth AG, Kristinsson J, Fagerhol MK, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol. 1993;28(12):1073-6
17. Vestergaard TA, Nielsen SL, Dahlerup JF, Hornung N. Fecal calprotectin: assessment of a rapid test. Scand J Clin Lab Invest. 2008;68(4):343-7
18. Sofar. Cal Detect. Available from: http://www.sofar.ro/sistemediagnosticare/cal-detect.html. Accessed in 2014 (Aug 15)
19. Dranga M, Dumitrescu G, Badea M, et al. The semi-quantitative calprotectin rapid test-is it useful in inflammatory bowel disease? Rev Med Chir Soc Med Nat Iasi. 2012;116(3):761-5
20. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997;314(7083):779-82
21. Tursi A, Brandimarte G, Elisei W, et al. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis. 2009;24(1):49-55
22. Schroder O, Naumann M, Shastri Y, Povse N, Stein J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther. 2007;26(7):1035-42
23. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47(6):804-11
24. Chaudhary NA, Truelove SC. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med. 1962;31:307-22
25. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003;125(6):1651-9
26. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol. 2003;98(7):1578-83
27. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102(4):803-13
28. Hamalainen A, Sipponen T, Kolho KL. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol. 2011;17(47):5166-71
29. Meling TR, Aabakken L, Roseth A, Osnes M. Faecal calprotectin shedding after short-term treatment with non-steroidal antiinflammatory drugs. Scand J Gastroenterol. 1996;31(4):339-44
30. Garcia Sanchez Mdel V, Gonzalez R, Iglesias Flores E, et al. Precision diagnostica de la calprotectina fecal para predecir una colonoscopia patologica [Diagnostic value of fecal calprotectin in predicting an abnormal colonoscopy]. Med Clin (Barc). 2006;127(2):41-6
31. Husebye E, Ton H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol. 2001;96(9):2683-7
32. Grad C, David L, Portincasa P, Dumitrascu DL. Diagnostic value of calprotectin in irritable bowel syndrome and in inflammatory bowel disease. Rom J Intern Med. 2012;50(1):3-6.